Results 121 to 130 of about 1,212,195 (296)

Intelligent Programmable Membrane Nanosponge for Early Virus Blocking

open access: yesAdvanced Science, EarlyView.
A smart programmable nanosponge (ACNPs) displays high‐density viral receptors on its membrane and encapsulates fusion inhibitors to capture virions at the infection source through competitive binding and blocks their entry through protease inhibition for ultra‐early cascade interception. This modular, mucus‐penetrating platform shifts antiviral defence
Ze Chen   +17 more
wiley   +1 more source

Targeted expression of the anti-HIV microbicide lectin griffithsin in maize and tobacco [PDF]

open access: yes, 2013
Includes abstract.Includes bibliographical references.Plants are emerging as cost friendly alternative production systems for a variety of pharmaceuticals. Numerous therapeutic proteins have been produced in plant systems (Giddings et al., 2000; Ma et al.
Stark, Hester Catharina (Therese)
core   +1 more source

Beyond Simple Mimicry: Next‐Generation Geometric Architectures and Future Paradigms in Small‐Molecule and Macrocyclic Peptidomimetics

open access: yesAngewandte Chemie, EarlyView.
Peptide‐to‐Small Molecule Paradigm: Peptidomimetics have evolved from simple mimicry toward drug‐like scaffolds supported by increasing clinical successes. This Perspective highlights the geometric design principles—linear repetition, convergent fusion, and cyclization—defining the next‐generation peptidomimetic architectures capable of targeting ...
Jesang Lee   +5 more
wiley   +2 more sources

Outcomes for efavirenz versus nevirapine-containing regimens for treatment of HIV-1 infection: a systematic review and meta-analysis. [PDF]

open access: yes, 2013
INTRODUCTION: There is conflicting evidence and practice regarding the use of the non-nucleoside reverse transcriptase inhibitors (NNRTI) efavirenz (EFV) and nevirapine (NVP) in first-line antiretroviral therapy (ART). METHODS: We systematically reviewed
Pillay, Prinitha   +16 more
core   +1 more source

Interleukin‐39 is a Prognostic Biomarker and Therapy Target for Sepsis

open access: yesAdvanced Science, EarlyView.
Sepsis triggers a significant increase in IL‐39 production, with circulating levels markedly elevated and positively correlated with disease severity and poor clinical prognosis in sepsis patients. Mechanistically, macrophage‐derived IL‐39 activates the GP130 signaling pathway via a ligand‐receptor interaction, thereby fueling the pro‐inflammatory ...
Feng‐zhi Zhang   +9 more
wiley   +1 more source

Validation study of an automated chemiluminiscence assay to detect HIV antibodies in oral fluid specimens. [PDF]

open access: yesEur J Clin Microbiol Infect Dis, 2022
González V   +7 more
europepmc   +1 more source

FTSJ3‐Mediated 2′‐O‐Methylation of HSPA5 mRNA Stabilizes BOP1 via SUMOylation to Drive DRP1‐Dependent Mitochondrial Fission and Fatty Acid Oxidation in Lung Squamous Cell Carcinoma

open access: yesAdvanced Science, EarlyView.
The RNA methyltransferase FTSJ3 drives lung squamous cell carcinoma progression by catalyzing 2′‐O‐methylation of HSPA5 mRNA, which stabilizes BOP1 through SUMOylation and activates DRP1/SREBP1‐mediated mitochondrial fission and fatty acid oxidation. Targeting this axis with liposomal siRNA potently suppresses tumor growth and metastasis ABSTRACT Lung ...
Qin Hu   +4 more
wiley   +1 more source

AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury

open access: yes, 2022
Hepatology, EarlyView.
Robert J. Fontana   +6 more
wiley   +1 more source

Is an HIV vaccine possible?

open access: yesBrazilian Journal of Infectious Diseases
The road to the discovery of a vaccine for HIV has been arduous and will continue to be difficult over the ensuing twenty years. Most vaccines are developed by inducing neutralizing antibodies against the target pathogen or by using attenuated strains of
Nancy A. Wilson, David I. Watkins
doaj   +1 more source

In vivo engineered B cells secrete high titers of broadly neutralizing anti-HIV antibodies in mice. [PDF]

open access: yesNat Biotechnol, 2022
Nahmad AD   +17 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy